PLXDC1

Across TCGA pan-cancer cohorts, PLXDC1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLXDC1 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLXDC1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PLXDC1 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, STAD, and BRCA are the cancer types where PLXDC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.058	0.712	<.001	27	view →
STAD	DFS	Median	All	1.000	0.379	.011	14	view →
BRCA	OS	Median	III,IV	0.313	0.834	.004	14	view →
SKCM	OS	Median	All	0.470	0.784	<.001	14	view →
SARC	OS	Median	All	0.126	0.860	<.001	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLXDC1–HNSC (OS)

Open the HNSC breakdown →